roduction of acquired 16S rRNA methyltransferase (16S RMTase) is an emerging mechanism of high-level aminoglycoside resistance in clinically relevant Gram-negative bacteria. So far, seven plasmid-mediated 16S RMTases have been reported worldwide (1). Of the known 16S RMTases, RmtE has been reported in only one Escherichia coli strain, which was identified from a calf in the United States (2). Here, we report the first documented case of human infection by RmtE-producing E. coli.
racycline, chloramphenicol, and trimethoprim-sulfamethoxazole.
Phylogenetic group D ST354 E. coli has been identified in association with CMY-2 production in humans (7) and a stray dog (8) . The incompatibility group of the plasmids was not reported in these studies, but bla CMY-2 is known to be most commonly encoded on IncA/C plasmids, followed by IncI1 plasmids (9) . One may therefore hypothesize that this gene was acquired by an IncA/C, bla CMY-2 -carrying plasmid in E. coli YDC637.
In summary, we here report a group D ST354 E. coli coproducing RmtE and CMY-2 that caused invasive human disease. The IncA/C plasmid carrying rmtE and bla CMY-2 also conferred resistance to tetracycline, chloramphenicol, and trimethoprim-sulfamethoxazole in addition to aminoglycosides and cephalosporins, making it an exceptionally multidrug-resistant plasmid. 
